Second-Generation ALK Inhibitors: Filling the Non “MET” Gap

Por Ramalingam, Suresh S., Khuri, Fadlo R.
Publicado no Cancer Discov (2014)

Energizing the search to target LKB1-mutant tumors

Por Marcus, Adam I., Khuri, Fadlo R.
Publicado em 2013

Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation

Por Owonikoko, Taofeek K., Khuri, Fadlo R.
Publicado em 2013

Can We Achieve an 80% Screening Rate for Colorectal Cancer by 2018 in the United States?

Por Paskett, Electra D., Khuri, Fadlo R.
Publicado no Cancer (2015)

A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides

Por Du, Yuhong, Khuri, Fadlo R, Fu, Haian
Publicado em 2008

Targeting protein-protein interactions as an anticancer strategy

Por Ivanov, Andrei A., Khuri, Fadlo R., Fu, Haian
Publicado em 2013

Coupling of endoplasmic reticulum stress to CDDO-Me-induced upregulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation

Por Zou, Wei, Yue, Ping, Khuri, Fadlo R., Sun, Shi-Yong
Publicado em 2008

Pleiotropic functions of EAPII/TTRAP/TDP2: Cancer development, chemoresistance and beyond

Por Li, Chunyang, Sun, Shi-Yong, Khuri, Fadlo R, Li, Runzhao
Publicado em 2011

mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis

Por Zhao, Liqun, Yue, Ping, Khuri, Fadlo R., Sun, Shi-Yong
Publicado em 2013

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition

Por Yao, Weilong, Yue, Ping, Khuri, Fadlo R., Sun, Shi-Yong
Publicado no Oncotarget (2015)

Celecoxib Antagonizes Perifosine's Anticancer Activity Involving a Cyclooxygenase-2-Dependent Mechanism

Por Elrod, Heath A., Yue, Ping, Khuri, Fadlo R., Sun, Shi-Yong
Publicado em 2009

Altered glutamine metabolism and therapeutic opportunities for lung cancer

Por Mohammed, Mohammed A., Deng, Xingming, Khuri, Fadlo R., Owonikoko, Taofeek K.
Publicado em 2013

Transcriptional Regulation of YWHAZ, the Gene Encoding 14-3-3ζ

Por Kasinski, Andrea, Dong, Xueyuan, Khuri, Fadlo R., Boss, Jeremy, Fu, Haian
Publicado em 2014

Perspective on the National Comprehensive Cancer Network’s (NCCN) Clinical Practice Guidelines for Smoking Cessation

Por Ostroff, Jamie S., Goffin, John R., Khuri, Fadlo R., Warren, Graham W.
Publicado no J Oncol Pract (2015)

The eIF4E/eIF4G Interaction Inhibitor 4EGI-1 Augments TRAIL-Mediated Apoptosis through c-FLIP Down-regulation and DR5 Induction Independent of Inhibition of Cap-Dependent Protein T...

Por Fan, Songqing, Li, Yikun, Yue, Ping, Khuri, Fadlo R, Sun, Shi-Yong
Publicado em 2010

Retinoic acid enhances TRAIL induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression

Por Dhandapani, Latha, Yue, Ping, Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Publicado em 2011

14-3-3 proteins as potential therapeutic targets

Por Zhao, Jing, Meyerkord, Cheryl L., Du, Yuhong, Khuri, Fadlo R., Fu, Haian
Publicado em 2011

The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells

Por Zhao, Liqun, Yue, Ping, Lonial, Sagar, Khuri, Fadlo R, Sun, Shi-Yong
Publicado em 2011

Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and EGCG: the role of p53-dependent inhibition of nuclear factor-kappaB

Por Amin, ARM R., Khuri, Fadlo R., Chen, Zhuo (Georgia), Shin, Dong M.
Publicado em 2009

Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation

Por Koo, Junghui, Wu, Xiaoyun, Mao, Zixu, Khuri, Fadlo R., Sun, Shi-Yong
Publicado no J Biol Chem (2015)